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A B S T R A C T
Objectives: Mappings to convert clinical measures to preference-based measures of health such as the EQ-5D-3L are
sometimes required in cost-utility analyses. We developed mappings to convert best-corrected visual acuity (BCVA) to the
EQ-5D-3L, the EQ-5D-3L with a vision bolt-on (EQ-5D V), and the Visual Functioning Questionnaire-Utility Index (VFQ-UI)
in patients with macular edema caused by central retinal vein occlusion.
Methods: We used data from Lucentis, Eylea, Avastin in vein occlusion (LEAVO), which is a phase-3 randomized controlled trial
comparing ranibizumab, aflibercept, and bevacizumab in 463 patients with observations at 6 time points. We estimated adjusted
limited dependent variable mixture models consisting of 1 to 4 distributions (components) using BCVA in each eye, age, and sex
to predict utility within the components and BCVA as a determinant of component membership. We compared model fit using
mean error, mean absolute error, root mean square error, Akaike information criteria, Bayesian information criteria, and visual
inspection of mean predicted and observed utilities and cumulative distribution functions.
Results:Mean utility scores were 0.82 for the EQ-5D-3L, 0.79 for the EQ-5D V, and 0.88 for the VFQ-UI. The best-fitting models
for the EQ-5D and EQ-5D V had 2 components (with means of approximately 0.44 and 0.85), and the best-fitting model for
VFQ-UI had 3 components (with means of approximately 0.95, 0.74, and 0.90).
Conclusions:Models with multiple components better predict utility than those with single components. This article provides
a valuable addition to the literature, in which previous mappings in visual acuity have been limited to linear regressions,
resulting in unfounded assumptions about the distribution of the dependent variable.
Keywords: bolt-off, bolt-on, crosswalk, EQ-5D, EQ-5D vision, mapping, visual acuity, VFQ, VFQ-UI.
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Introduction
Mappings to convert clinical measures to health utilities may
be required for economic evaluations in which either health util-
ities were not reported in the clinical effectiveness studies or in
which there is a need to relate modeled clinical outcomes to
health utilities in the long-term. Health utilities may be generated
using generic preference-based measures such as the EQ-5D or
more specific measures such as the Visual Functioning
Questionnaire-Utility Index (VFQ-UI) in visual disorders.
A multicenter phase 3 double-masked randomized controlled
noninferiority trial comparing intravitreal therapy with ranibizu-
mab (Lucentis) versus aflibercept (Eylea) versus bevacizumab
(Avastin) for macular edema due to central retinal vein occlusion
(CRVO; LEAVO) was a three-arm study of 463 patients over a 100-
week period.1 The cost-effectiveness analysis comprised 2 parts:
an economic evaluation alongside the clinical trial and an eco-
nomic model to analyze the cost-effectiveness over a longer time
horizon. LEAVO included 3 preference-based measures of utility:
the EQ-5D five level, the EQ-5D five level with vision bolt-on (EQ-
5D V), and the VFQ-UI. The EQ-5D five level with and without the
vision bolt-on were converted to the 3-level version using the
crosswalk of van Hout et al2 as recommended by the National
Institute for Health and Care Excellence (NICE) in its methods
guide.3 In the economic analysis, these measures could be used
directly in the within-trial analysis. The economic model predicted
visual acuity until all patients had died and thus required a
mapping to relate visual acuity to health utility.
The EQ-5D asks patients to rate their health across 5 di-
mensions: mobility, self-care, usual activities, pain/discomfort,
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and anxiety/depression. In the 3-level (3L) version, each dimen-
sion has 3 levels: no problems, some problems, and extreme
problems.4 In the 5-level (5L) version, each dimension has 5
levels: no problems, slight problems, moderate problems, severe
problems, and extreme problems.5 The patient’s responses to the
5 dimensions are combined into a single-digit number repre-
senting the patient’s health state. A sample of 3L health states was
valued using a representative sample of the UK population using
the time trade-off method, and regression models were used to
generate a tariff of values for all health states.6 A value set has also
been produced for the EQ-5D-5L,7 although quality assurance has
raised concerns about the data.8
A bolt-on exists for the EQ-5D, which also asks patients about
their vision. In the 5L version, there are 5 levels: no problems,
slight problems, moderate problems, severe problems, and
extreme problems. In the 3L version, there are 3 levels: no prob-
lems, some problems, and extreme problems. A scoring algorithm
exists for the vision bolt-on to the EQ-5D-3L, whereby a decre-
ment of 0.0378 is subtracted from the EQ-5D-3L score for patients
who report some problems with vision and a decrement of 0.130
is subtracted from the EQ-5D-3L score for patients who report
extreme problems with vision.9
The VFQ-UI was developed from the National Eye Institute
Visual-Function Questionnaire-25, which contains 25 items with 5
or 6 response levels. The VFQ-UI asks patients to rate their health
across 6 dimensions. Near vision, social vision, and distance vision
each have 4 levels relating to the level of difficulty (no, little, mod-
erate, or extreme) that the patient has in specific activities. Role
difficulty asks whether the patient is not limited, limited a little of
the time, limited some of the time, or limited in how long they can
work or do other activities. Vision dependency asks whether the
patient does not have to stay home or has to stay home some,most,
or all of the time. Mental health asks whether the patient does not
worry or worries some, most, or all of the time about doing this,
which will embarrass themselves or others.10 A sample of VFQ-UI
health states was valued using participants from Australia, Can-
ada, the United Kingdom, and the United States using the time
trade-off method, and regression models were used to develop a
scoring algorithm for all potential health states.11
The primary outcome in LEAVO was the change in best-
corrected visual acuity (BCVA) of the study eye measured using
early treatment for diabetic retinopathy study (ETDRS) letter score
from baseline to 100 weeks. The ETDRS chart consists of 14 rows
of 5 letters, with an equal difficulty on each row but with
decreasing size. For patients who could read 20 or more letters
correctly at 4m, their BCVA score was the number of letters read at
4m plus 30. For patients who could read fewer than 20 letters
correctly at 4m, their BCVA score was calculated as the total
number of letters read correctly at 4m plus the total number of
letters read correctly at 1m in the first 6 lines.12 A higher BCVA
score indicates better vision. The economic model used BCVA
letter scores in both the study and nonstudy eye to model disease
progression. To model quality of life, BCVA ETDRS letter scores
were therefore linked to EQ-5D, EQ-5D V, and VFQ-UI. Previous
research has shown that BCVA letter scores in both eyes are
important in predicting utility.13–16 We aimed to develop a map-
ping to predict EQ-5D, EQ-5D V, and VFQ-UI scores from the BCVA
score of the study and nonstudy eye.
Methods
Data
LEAVO collected EQ-5D-5L, vision bolt-on, and VFQ-UI re-
sponses in addition to BCVA ETDRS scores for both eyes (among
othermeasures) atweeks 0,12, 24, 52, 76, and 100.We used the van
Hout crosswalk2 (consistent with guidance from NICE17) to convert
theEQ-5D-5L responses toEQ-5D-3L scores.Wevalued theEQ-5DV
scores by subtracting 0.0378 for patients with level or moderate
visionproblemsand0.130 forpatientswith severeorextremevision
problems.9We used the VFQ-UI scoring system described by Rentz
et al.11We combined data from all 6 visits to maximize the number
of observations. At each observation, we generated variables for the
better-seeing eye (BSE) and worse-seeing eye (WSE) according to
whether the BCVA score was higher in the study or nonstudy eye.
Statistical Analysis
The EQ-5D-3L has a distinctive distribution, with a lower bound
of –0.594 and an upper bound of 1. It displays a multimodal distri-
butionwith amass of observations at 1 and a gap between 1 and the
next-best health state (0.906 when crosswalking 5L to 3L). These
propertiesmean that standard statisticalmodels areoftenapoorfit,
and sowe used bespokemodels developed formodeling EQ-5D-3L:
adjusted limiteddependentvariablemixturemodels (ALDVMMs).18
The ALDVMM is based on mixtures of bespoke distributions that
accommodate the limits to the EQ-5D-3L distribution at full health,
at the worst health state, and the gap between full health and the
next feasible health state. In addition, being a mixture model, it
provides a flexible semiparametric framework for modeling dis-
tributions with unusual shapes. Although initially developed for
modeling the EQ-5D-3L, themodel has been shown to be applicable
to other preference-based measures.19 Because the EQ-5D V is
calculated from the EQ-5D, it has a similar distribution. The VFQ-UI
is scored between 0.343 and 0.956, and its distribution has different
characteristics from that of the EQ-5D.
ALDVMMs are flexible models that feature multiple compo-
nents; each component’s distribution has different parameters.
Additional variables predict the probability of each observation
belonging to each component. We estimated ALDVMMswith 1 to 4
components. We included BSE BCVA, WSE BCVA, and the interac-
tion between them (to allow for the effect of BSE to varywithWSE);
age; and sex as independent variables to predict the EQ-5D, EQ-5D
V, or VFQ-UI within the components. We considered BSE and WSE
BCVA as determinants of component membership. We did not
include the trial arm as an independent variable because therewas
no statistically significant difference betweenutility in the3 arms in
the trial,20 and it is anticipated that an intervention would affect
utility by affecting the BCVA score.
To compare results across models, we considered standard model
fit measures/criteria such as mean error mean absolute error (MAE),
root mean square error (RMSE), Akaike information criteria (AIC),
Bayesian information criteria (BIC), and graphical methods for model
selection in mapping.19 Amean error closer to zero and smaller MAE,
RMSE, AIC, and BIC indicated a better fit. Nevertheless, standard
measures based on “errors” (difference between the data and the
model prediction) often provide conflicting results because they are
based on different scoring functions. For example, RMSE penalizes the
existence of large outliers more than MAE does. Both AIC and BIC are
likelihood-based criteriawith a penalty formodel complexity, but the
penalty BIC imposes tends to be larger, often resulting in AIC and BIC
selecting models with different number of parameters. Because of
these issues, graphical methods have been shown to be essential for
mapping model selection. Specifically, we plotted the mean of the
predicted utility scores with the mean observed values by BSE and
WSEBCVAscores.Wealsosimulateddata fromthemodelsandplotted
the cumulative distribution functions comparing simulated with
observed data across the severity range. We followed good practice
guidance produced by the International Society for Pharmacoeco-
nomics and Outcomes Research.21
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Results
There were 2778 observations in total (6 time points for 463
patients). There were 2558 observations, which included data for
age, sex, and BCVA in both eyes. Utility data were available for
2470 of these observations for the EQ-5D, 2321 for the EQ-5D V,
and 2481 for the VFQ-UI. The distributions of EQ-5D, EQ-5D V, and
VFQ-UI scores and for the BSE and WSE BCVA ETDRS scores are
shown in Figure 1. The EQ-5D displayed its typical multimodal
distribution, with a spike of 38.47% of observations at 1, a gap
between 1 and 0.906, and peak around 0.8 and a long tail to the
left. The EQ-5D V had a similar shape, with a spike at 1 (repre-
senting 18.55% of patient observations in full health according to
the EQ-5D who have no vision problems) and a gap between 1 and
the next-best health state (here, this is 0.962, as 19.46% of patients
have full health according to the EQ-5D but mild vision problems).
The values in the peak at about 0.8 and the tail were lower for the
EQ-5D V than for the EQ-5D because of the decrements for vision
problems. Because of vision decrements, there were slightly more
observations less than 0 for the EQ-5D V than for the EQ-5D (1.38%
vs 0.86%). The VFQ-UI displayed a highly skewed distribution, with
a peak at about 0.9 and a long left tail, similar to its distribution in
previous studies.14
Descriptive statistics are shown in Table 1. Means and pro-
portions for BCVA, age, and sex were calculated from the 2558
observations with these data available. Means for the utility
measures excluded patients where utility data were not available.
The Spearman correlation coefficients between the 3 utility
measures and BSE, WSE, age, and sex (Appendix Table 1 in Sup-
plemental Materials found at https://doi.org/10.1016/j.jval.2020.
03.008) demonstrated a statistically significant correlation
(at the 5% level) between the variables.
Model Fit Statistics
EQ-5D
Table 2 presents the fit statistics for the ALDVMMs for EQ-5D.
Within the 1- and 2-component models, adding an interaction
term worsened the model fit, as demonstrated by increased AIC,
BIC, MAE, and RMSE for the 2-component model. We therefore
omitted this variable from models with further components.
Within the 2-component model, using the BSE to predict
component membership improved the model fit and additionally
using the WSE further improved the model fit. We therefore chose
between 1-, 2-, 3-, and 4-component models without the
BSE*WSE interaction term and using BSE and WSE to determine
component membership. The 2-, 3-, and 4-component models had
the same RMSE and similar MAE (slightly higher for the 3 and 4
components than 2 components), but the BIC was lowest for the
2-component model (model 6).
EQ-5D V
Supplementary Table 2 (in Supplemental Materials found at
https://doi.org/10.1016/j.jval.2020.03.008) presents thefit statistics
for the ALDVMM models for the EQ-5D V. As with the EQ-5D, the
interaction termworsened themodelfit, andusing theBSEandWSE
to predict componentmembership improved themodel fit. The BIC
was lowest for the 2-component model with component mem-
bership predicted by BSE and WSE, whereas the mean error, MAE,
and RMSE were similar for the 2-, 3-, and 4-component models.
Figure 1. Distribution of the EQ-5D, EQ-5D V, and VFQ-UI baseline scores and the BSE and WSE baseline scores.
BSE indicates better-seeing eye visual acuity; EQ-5D V, EQ-5D with vision bolt-on; VFQ-UI, Visual Functioning Questionnaire-Utility Index; WSE, worse-seeing
eye visual acuity.
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VFQ-UI
Supplementary Table 3 presents the fit statistics for the
ALDVMMmodels for the VFQ-UI. We found that the 3-component
model with component membership predicted by the BSE and
WSE had the lowest BIC, whereas the mean error, MAE, and RMSE
were similar between the 2-, 3-, and 4-component models.
Comparison of Mean Predicted and Observed Utility
Scores
Figure 2 presents the mean predicted and observed utility
scores for the 2-component models for the EQ-5D and EQ-5D V
and the 3-component model for the VFQ-UI (all with within-
component variables for BSE, WSE, age, and sex and with
component membership predicted by BSE and WSE), against
BSE and WSE scores. The graphs of the mean predicted and
observed utility scores for models with a higher number of
components (not presented here) did not indicate a better
prediction and so did not change the decisions regarding the
best-fitting models. Generally, we see that utility increases as
BSE and WSE increase, but the observed values are
nonmonotonic for BCVA scores less than 40. The observed
utility values for BCVA scores less than 40 are nonmonotonic
because of the small number of observations and the potential
for visual acuity loss to be caused by other conditions such as
retinal detachment and endophthalmitis in addition to CRVO.
For all utility measures, the predicted values lie furthest from
the observed values for very low BSE and WSE scores. For lower
BSE and WSE scores, the confidence intervals for the utility
scores are much wider than for higher BSE and WSE scores; this
is because there are few observations at low BSE and WSE
scores (see Figure 1). At higher BSE and WSE scores, the pre-
dicted mean values appear to lie very close to the observed
mean values for all 3 utility measures. The mean predicted
utilities lie closer to the mean observed scores for the VFQ-UI
than for the EQ-5D and EQ-5D V (particularly at lower BSE
and WSE scores). This is unsurprising when considering that
the VFQ is focused on vision, whereas the EQ-5D and EQ-5D V
also measure other elements of health-related quality of life.
Cumulative Distribution Functions
Figure 3 shows the cumulative distribution functions for the
simulated data for the 2-component models for the EQ-5D and
EQ-5D V and the 3-component model for the VFQ-UI (all with
within-component variables for BSE, WSE, age, and sex and with
component membership predicted by BSE and WSE). The cu-
mulative distribution functions for the models with 1 compo-
nent (not presented here) demonstrated a disparity between the
actual and modeled data, which reduced when additional com-
ponents were added. There was little difference between the
actual and modeled data for the 2-, 3-, and 4-component
models, so this did not change the decision regarding the best-
fitting models.
Within-Component Means and Probabilities
Table 3 presents the mean utility for each component and the
probability that a patient in LEAVO was in that component for
each utility measure. The 2-component models for the EQ-5D
and EQ-5D V had 1 mean approximately equal to 0.44 and the
other approximately equal to 0.85, and increasing the number of
components added more means around the higher value. None
Table 1. Descriptive statistics of best corrected visual acuity, EQ-
5D with and without the vision bolt-on and the Visual Functioning
Questionnaire-Utility Index from the LEAVO study data.
Variable Mean 6 SD Minimum Maximum
EQ-5D index score 0.820 6 0.211 20.287 1
EQ-5D vision
bolt-on score
0.792 6 0.220 20.295 1
VFQ-UI score 0.881 6 0.115 0.400 0.980
Better-seeing
eye BCVA score
83.795 6 9.278 2 100
Worse-seeing
eye BCVA score
62.664 6 18.965 0 98
Age 70.279 6 12.785 21.664 98.226
Male, n (%) 1,466 (57.31%)
BCVA indicates best-corrected visual acuity; SD, standard deviation; VFQ-UI,
Visual Functioning Questionnaire-Utility Index.
Table 2. Model fit statistics for the ALDVMMs for EQ-5D.
Model Number of
components
Within-
component
variables
Between-
component
variables
Log
likelihood
AIC BIC Mean
error
MAE RMSE
1 1 BSE, WSE, age, sex NA 2704.413 1420.8250 1455.6970 0.0039 0.1445 0.1987
2 1 BSE, WSE, BSE*WSE,
age, sex
NA 2704.412 1422.8240 1463.5080 0.0039 0.1445 0.1987
3 2 BSE, WSE, age, sex Constant 2479.682 985.3648 1060.9200 20.0017 0.1435 0.1986
4 2 BSE, WSE, BSE*WSE,
age, sex
Constant 2477.872 985.7431 1072.9230 20.0013 0.1437 0.1988
5 2 BSE, WSE, age, sex BSE 2476.116 980.2326 1061.6000 20.0006 0.1436 0.1987
6 2 BSE, WSE, age, sex BSE, WSE 2467.949 965.8980 1053.0780 20.0007 0.1435 0.1982
7 3 BSE, WSE, age, sex Constant 2456.618 953.2355 1069.4750 20.0009 0.1438 0.1986
8 3 BSE, WSE, age, sex BSE, WSE 2449.198 946.3959 1085.8830 20.0009 0.1437 0.1982
9 4 BSE, WSE, age, sex Constant 2441.025 936.0499 1092.9730 20.0012 0.1437 0.1985
10 4 BSE, WSE, age, sex BSE, WSE 2419.682 905.3647 1097.1600 20.0003 0.1421 0.1960
AIC indicates Akaike information criteria; BIC, Bayesian information criteria; BSE, better-seeing eye visual acuity; MAE, mean absolute error; NA, not applicable; RMSE,
root mean square error; WSE, worse-seeing eye visual acuity.
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Figure 2. Mean predicted and observed utility scores for 2-component models for the EQ-5D and EQ-5D V and 3-component model for
the VFQ-UI.
BCVA indicates best-corrected visual acuity; CI, confidence interval; EQ5D V, EQ-5D with vision bolt-on; VFQ-UI, Visual Functioning Questionnaire-Utility
Index.
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of the models picked up the probability mass at 0 that is usually
observed for EQ-5D. This is likely to be because our models
considered component membership as a function of visual
acuity alone, but visual acuity is not the only contributing factor
to the EQ-5D, as many patients in LEAVO also had other
comorbidities, and the EQ-5D and EQ-5D V decreased as the
number of comorbidities increased. In the economic model for
which the mappings were designed, only visual acuity was
modeled and not comorbidities, so the utilities relied on an
average number of comorbidities. Using the VFQ-UI, additional
components were clustered around 0.8 to 0.9, where the bulk of
observations lay.
Discussion
We found that the EQ-5D and EQ-5D V were best predicted
using 2-component models (the VFQ-UI using 3-component
models) where utility within each component was a function of
age, sex, and visual acuity in both eyes and the probability of
component membership was a function of visual acuity in both
eyes. Our mappings were designed for use in an economic model
in macular edema secondary to CRVO, to allow utility to be pre-
dicted long-term from visual acuity.
We provide mappings for 3 measures of utility. An Excel tool
that calculates a patient’s utility using the 3 measures when a user
inputs their characteristics is provided at https://figshare.shef.ac.
uk/articles/Utility_calculator_for_visual_acuity/9873731/1. As a
generic measure of health, the EQ-5D allows comparisons across
disease areas and is NICE’s preferred measure of utility for adults.3
Nevertheless, previous research has expressed concern regarding
Table 3. Mean utility for each component, and the probability
that a patient in LEAVO was in that component for each utility
measure.
Utility
measure
Number of
components
Component Mean Probability
EQ-5D 2 1 0.869 .872
2 0.443 .127
3 1 0.883 .369
2 0.839 .535
3 0.386 .096
4 1 0.836 .571
2 0.842 .110
3 0.498 .092
4 0.932 .226
EQ-5D-V 2 1 0.442 .142
2 0.843 .858
3 1 0.842 .892
2 0.554 .003
3 0.428 .134
4 1 0.742 .446
2 0.864 .447
3 0.775 .082
4 0.330 .081
VFQ-UI 2 1 0.945 .609
2 0.791 .391
3 1 0.946 .588
2 0.735 .250
3 0.896 .161
4 1 0.897 .153
2 0.587 .049
3 0.946 .590
4 0.748 .208
EQ-5D V indicates EQ-5D with vision bolt-on; VFQ-UI, Visual Functioning
Questionnaire-Utility Index.
Figure 3. Cumulative distribution function for the simulated
data for the 2-component models for the EQ-5D and EQ-5D V and
3-component model for the VFQ-UI.
EQ-5D V indicates EQ-5D with vision bolt-on; VFQ-UI, Visual Functioning
Questionnaire-Utility Index.
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the validity of the EQ-5D in visual disorders22 and has identified
vision as an area in which bolt-ons may be required.23 The VFQ-UI
has been found to be more sensitive to changes in visual acuity.14
Although our analysis does not permit direct comparison of
goodness of fit between the different measures, visual inspection
confirms that the VFQ-UI appears to more closely align with BSE
and WSE BCVA than with the EQ-5D. By developing 3 mappings,
we provide options for analysts to use these different measures to
estimate utility.
Our analyses found that models with multiple components
fitted the data better than those with single components. This is
consistent with findings from other disease areas, in which
ALDVMMs with multiple components outperform linear re-
gressions using ordinary least squares estimation.21,24 Neverthe-
less, previous mappings in visual acuity have been limited to
ordinary least squares,14 and so our analyses provide a valuable
addition to the literature.
The inclusion of age and sex within components was both
found to improve model fit. These variables are included in eco-
nomic models as standard, and including them in utility estima-
tion is important for accurately modeling utility over a long time
horizon. Consistent with Brazier et al,14 but in contrast with
Claxton et al,13 we found that the inclusion of an interaction term
between the BSE and WSE did not improve the model fit.
Although visual acuity was a significant predictor within
components and improved model fit for predicting component
membership, it did not pick up a separate component for pa-
tients with utility at or below 0 for EQ-5D and EQ-5D V. This may
be because of the presence of comorbidities within the popula-
tion, which contributed to lower utility scores. Changing a per-
son’s visual acuity alone would not change their underlying
comorbidities and so would not change their probability of
belonging to an additional component with different comor-
bidities. The LEAVO economic model did not specifically include
comorbidities and instead implicitly assumed that patients have
an average comorbidity profile, reflecting the likely data avail-
able to users of the mapping model and in line with good
practice guidance.21
In patients with CRVO, hypertension is a common comorbid-
ity.25,26 Our mappings are therefore appropriate for use in eco-
nomic analysis, but we note that the exclusion of comorbidities
does limit the accuracy of modeling utility. Macedo et al27 found
that the EQ-5D-3L utility index is associated with the number of
reported comorbidities. Brazier et al14 found that including
comorbidities improved model fit in predicting both the EQ-5D
and VFQ-UI. We were unable to develop a mapping that
included comorbidities, as these were recorded only at baseline in
the LEAVO study and may have changed over the 100-week trial
duration.
A limitation of the robust estimator of the variance used in
the statistical model was the inclusion of repeated observations
of the same patients to increase the number of observations
available. A cluster-robust estimator of the standard errors could
have been used, which is robust in the presence of the correla-
tion between observations for each individual. This does not
change the estimated coefficients from the ALDVMM and affects
only the standard errors used in the probabilistic sensitivity
analyses.
It is unclear whether our analyses could be applied in visual
disorders other than macular edema secondary to CRVO. We note
that some previous economic evaluations have assumed utilities
are common across visual disorders, for example, the use of util-
ities from age-related macular degeneration28 in scenario analysis
for an economic evaluation in macular edema secondary to
CRVO.16 Although it may be plausible to assume that the impact on
health-related quality of life of changing visual acuity is not
dependent on the underlying disease, the absolute utility values
may vary across conditions, particularly where comorbidities vary,
which would affect quality-adjusted life-year gains from mortality
benefits.
Conclusion
Our mappings can be used to predict the EQ-5D, EQ-5D V, and
VFQ-UI from BCVA. Our analyses found that including multiple
components in ALDVMMs improved model fit. Our analyses can be
used in economic evaluations to predict utility as a function of
variables routinely included in economic models for visual disor-
ders, but we note that other comorbidities may also contribute to
absolute utility scores.
Acknowledgments
The authors are grateful to Caroline Murphy (Kings Clinical Trials Unit),
Joanna Kelly (Kings Clinical Trials Unit), Toby Prevost (Imperial College
London), Joana Vasconcelos (Imperial College London), and Jayashree
Ramu (Moorfields Eye Hospital) for their time designing the case report
forms, checking the data management platform and data-monitoring
plans, and checking the database for data-monitoring committee meet-
ings and before database lock. This report presents independent research
funded by the UK National Institute for Health Research (NIHR) Health
Technology Assessment Programme (Grant 11/92/03) and supported by
the NIHR Biomedical Research Centre at Moorfields Eye Hospital. The
views expressed in this publication are those of the authors and not
necessarily those of the NHS, the NIHR, or the Department of Health and
Social Care.
Supplemental Material
Supplementary data associated with this article can be found in the
online version at https://doi.org/10.1016/j.jval.2020.03.008.
REFERENCES
1. Hykin P, Prevost AT, Vasconcelos JC, et al. Clinical effectiveness of intravitreal
therapy with ranibizumab vs aflibercept vs bevacizumab for macular edema
secondary to central retinal vein occlusion: a randomized clinical trial. JAMA
Ophthalmol. 2019;137(11):1256–1264.
2. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-5D-5L:
mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health.
2012;15(5):708–715.
3. National Institute for Health and Care Excellence. Guide to the methods of
technology appraisal. https://www.nice.org.uk/process/pmg9. 2013.
Accessed June 19, 2019.
4. EuroQol Research Foundation. EQ-5D-3L. https://euroqol.org/eq-5d-
instruments/eq-5d-3l-about/. 2019. Accessed August 6, 2019.
5. EuroQol Research Foundation. EQ-5D-5L. https://euroqol.org/eq-5d-
instruments/eq-5d-5l-about/. 2019. Accessed August 8, 2019.
6. Dolan P. Modeling valuations for EuroQol health states. Med Care.
1997;35(11):1095–1108.
7. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related
quality of life: an EQ-5D-5L value set for England. Health Econ.
2018;27(1):7–22.
8. Hernandez Alava M, Pudney S, Wailoo A. Quality review of a proposed EQ5D-
5L value set for England. http://www.eepru.org.uk/wp-content/uploads/2
017/11/eepru-report-eq-5d-5l-27-11-18-final.pdf. 2018. Accessed September
3, 2019.
9. Longworth L, Yang Y, Young T, et al. Use of generic and condition-specific
measures of health-related quality of life in NICE decision-making: a sys-
tematic review, statistical modelling and survey. Health Technol Assess.
2014;18(9):1–224.
10. Kowalski JW, Rentz AM, Walt JG, et al. Rasch analysis in the development of a
simplified version of the National Eye Institute Visual-Function Question-
naire-25 for utility estimation. Qual Life Res. 2012;21(2):323–334.
11. Rentz AM, Kowalski JW, Walt JG, et al. Development of a preference-based
index from the National Eye Institute Visual Function Questionnaire-25.
JAMA Ophthalmol. 2014;132(3):310–318.
-- 7
12. Beck RW, Moke PS, Turpin AH, et al. A computerized method of visual acuity
testing: adaptation of the early treatment of diabetic retinopathy study
testing protocol. Am J Ophthalmol. 2003;135(2):194–205.
13. Claxton L, Hodgson R, Taylor M, Malcolm B, Pulikottil Jacob R. Simulation
modelling in ophthalmology: application to cost effectiveness of ranibizu-
mab and aflibercept for the treatment of wet age-related macular degener-
ation in the United Kingdom. Pharmacoeconomics. 2017;35(2):237–248.
14. Brazier J, Muston D, Konwea H, et al. Evaluating the relationship between
visual acuity and utilities in patients with diabetic macular edema enrolled
in intravitreal aflibercept studies. Invest Ophthalmol Vis Sci. 2017;58(11):
4818–4825.
15. National Institute for Health and Care Excellence. Ranibizumab for treating
visual impairment caused by macular oedema secondary to retinal vein oc-
clusion. https://www.nice.org.uk/guidance/ta283. 2013. Accessed July 1, 2019.
16. National Institute for Health and Care Excellence. Aflibercept for treating
visual impairment caused by macular oedema secondary to central retinal
vein occlusion. https://www.nice.org.uk/guidance/ta305. 2014. Accessed July
1, 2019.
17. National Institute for Health and Care Excellence. Position statement on use
of the EQ-5D-5L valuation set for England. https://www.nice.org.uk/about/
what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/
eq-5d-5l. 2018. Accessed June 19, 2019.
18. Hernandez Alava M, Wailoo A. Fitting adjusted limited dependent variable
mixture models to EQ-5D. Stata J. 2015;15(3):737–750.
19. Hernandez M, Wailoo A, Pudney S, Gray L, and Manca A. Modelling generic
preference based outcome measure: development and comparison of
methods. Health Technol Assess. In press.
20. Flight L, Alshreef A, Hykin P, et al. Intravitreal therapy with ranibizumab vs
aflibercept vs bevacizumab for macular oedema due to central retinal vein
occlusion: a within trial cost-utility analysis. Value Health. 2019;22(suppl
3):S664.
21. WailooAJ,Hernandez-AlavaM,MancaA, et al.Mapping to estimatehealth-state
utility fromnon-preference-based outcomemeasures: an ISPORGood Practices
for Outcomes Research Task Force report. Value Health. 2017;20(1):18–27.
22. Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based
measures of health-related quality of life in visual disorders. Value Health.
2012;15(1):118–127.
23. Finch AP, Brazier JE, Mukuria C, Bjorner JB. An exploratory study on using
principal-component analysis and confirmatory factor analysis to identify
bolt-on dimensions: the EQ-5D case study. Value Health. 2017;20(10):1362–
1375.
24. Hernandez Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted
limited dependent variable mixture models of EQ-5D questionnaire health
state utility values. Value Health. 2012;15(3):550–561.
25. Williamson TH. Central retinal vein occlusion: what’s the story? Br J Oph-
thalmol. 1997;81:698–704.
26. Sivaprasad S, Amoaku WM, Hykin P, Group RG. The Royal College of Oph-
thalmologists guidelines on retinal vein occlusions: executive summary. Eye
Lond. 2015;29:1633–1638.
27. Macedo AF, Ramos PL, Hernandez-Moreno L, et al. Visual and health out-
comes, measured with the activity inventory and the EQ-5D, in visual
impairment. Acta Ophthalmol. 2017;95(8):e783–e791.
28. Czoski-Murray C, Carlton J, Brazier J, et al. Valuing condition-specific health
states using simulation contact lenses. Value Health. 2009;12(5):793–799.
8 VALUE IN HEALTH - 2020
